Omada Health, Inc. (OMDA) Earnings Call Transcript
August 6, 2026
Earnings Call Speaker Segments
Thanks. Good afternoon, everyone, and welcome to the second quarter 2026 earnings conference call for Omada Health. With me on the call today are our Co-founder and CEO, Sean Duffy; our President, Wei-Li Shao; and our CFO, Steve Cook. Before we get started, I want to point out that we'll be talking about non-GAAP financial measures, which we believe are useful when assessing how Omada is performing. Details about how those measures tie back to our GAAP figures, including the reconciliations, can be found in the press release posted on our website. In addition, we'll be making forward-looking statements that reflect our current expectations and assumptions. Those statements carry risks and uncertainties, among them the factors described in our press release and in the risk factors contained in our SEC filings. Actual results may differ materially. We undertake no obligation to update any of these forward-looking statements. With that said, I'll hand things over to Sean.
Thanks, Craig. Good afternoon, all. Appreciate you being here with us. It's a pleasure to talk with you today about two key milestones in Omada's effort to change the trajectory of healthcare. First, we've just posted the best quarter in our history, with a record member count and our highest revenue and gross margin yet. Having served over 2 million members across our lifetime, holding commercial partnerships with the country's three biggest PBMs, and operating a model that's both proven and profitable, Omada stands stronger than at any point since it was founded. Second, it's because of that solid foundation that, more than 15 years after starting Omada, I feel ready to hand off leadership. Come January 1, 2027, Omada's President, Wei-Li Shao, will step into the Chief Executive Officer role. Many of you already know Wei-Li. He came aboard Omada 7 years ago as Chief Commercial Officer, and he's spent more than 4 years as our President. Wei-Li has earned the confidence of the team and our partners, consistently delivering dependable results along with new innovations that have placed Omada on what we see as a lasting long-term path. I can't wait to see Omada speed ahead into its next phase with Wei-Li at the helm. I feel just as excited to take on my new position as Executive Chair, where I'll remain on the management team, concentrating on long-term strategy, sparking partnerships, and pursuing other opportunities we think will generate the most value for Omada over time. Before passing things to Wei-Li for our operational performance discussion, I'd like to take a moment to spotlight what we care about most at Omada. It's the people we serve. I'm happy my organization offered Omada as a health option. Throughout the past year, the useful resources, everyday tracking, and advice from my diabetes specialist and health coach assisted me in hitting major milestones. Because of them, I achieved my goal weight, brought my diabetes fully under control, and entirely reversed my hypertension through lifestyle changes. I'm deeply thankful for that support. Stories like this are the reason we exist. While we discuss revenue, margins, and membership growth, all important measures of the business we're building, I want to remind everyone that behind each number is a person striving to live healthier, prevent disease progression, and receive the help they need in between visits to their physician. That mission keeps driving us forward. With that, I'll hand things to Wei-Li to cover the operational momentum we've observed throughout the business.
Thank you, Sean. Before we dive into the quarter, I want to express how grateful I am for the opportunity to take on the CEO position at Omada this January. It is genuinely an honor; this represents a crucial moment for Omada, as three powerful forces converge to shape what lies ahead for us. First, the commercial reach we are building enables us to provide best-in-class clinical care to an expanding number of Americans, which supports our mission of bending the curve. Second, GLP-1s and comparable therapies are powerful new tools that improve both the conditions we treat and the ways we treat them. Third, the rapid progress of AI is reshaping how personalized care can be delivered at scale. In my role as CEO, I will concentrate on turning these forces into better health outcomes for millions of Americans. We have shown that our model works, and our results support our ambitions. The time has come to push even harder toward our mission of bending the curve of chronic disease in America. As Sean mentioned, this quarter was record-setting and we are very proud of it. Q2 concludes an excellent first half of 2026 for Omada. Measured against the prior year, we delivered 43% revenue growth and improved gross margin by 700 basis points to 73% on a GAAP basis and by 600 points to 74% on a non-GAAP basis; we also generated $5 million in net income and $11 million in adjusted EBITDA, compared with a loss a year ago. Once again, we exceeded consensus, which allows us to lift our full year guidance. Even more importantly, we saw strong momentum across our programs, bringing total figures as of the end of the second quarter to 1.1 million, up 45% year-over-year. I will walk through our Q2 execution in the four areas we are focused on: covered lives, enrollment, engagement, and operating efficiency. Covered lives refers to the individuals who have benefits coverage that allows them to apply for and enroll in one or more of our programs through our employer, health plan, pharmacy benefit manager, and other customers. This number is refreshed annually. As of December 2025, our estimated eligible covered lives came to more than 25 million, and we are building on that base as we get ready for 2027. A quick note on how our commercial year generally follows a seasonal rhythm. New customer relationships are established during the first half. Historically, closing them occurs in the second half, and the annual benefit cycle begins in January. Q2 sits at the beginning of that cycle. Our commercial momentum in Q2 remained robust, just as it was last year. During the quarter, we added new customers across food service, national retail, public sector education, and industrial employers. These wins strengthen the pipeline we expect to close over the rest of the year, and we have seen particularly strong results in our newer offerings, such as our GLP-1 suite and cholesterol. The breadth of this says something fundamental about our business, reflected in a 600% increase in engagement we're seeing among those members. Chronic care assistance is needed across many kinds of employers and condition categories, and those are areas we are built to serve. Turning to the newer PBM channels, Q2 delivered continued progress as well. For one of those channels, now in its second year, a strong customer pipeline has taken shape going into the back half, and results are coming in above our expectations. The other channel — which is, in fact, our very first partner to add our prescribing program — is still at a very early stage in its sales efforts, yet the signals look encouraging. We also deepened our footprint inside relationships with customers we already had. The growth opportunity I'm most excited to talk about this quarter centers on Health Care Service Corporation, or HCSC — one of the largest Blues plans in the country and an organization we've worked with for several years via our prevention and Hypertension Programs. In Q2, we extended those offerings into HCSC's fully insured book of business in three additional states, bringing in 1.5 million covered lives that are scheduled to go live in 2027. Two things make this growth meaningful. First, HCSC exemplifies the kind of long-term partner we can expand with over time as we prove results across one program after another. Second, the fully insured piece sits at the benefit level, which means members may enroll on their own, with no employer sales cycle required downstream. That's the kind of channel dynamic we're trying to build for scale. We see Q2 as a strong quarter for the earlier portion of our commercial cycle. We posted new customer wins spanning a range of industries, made substantial headway in our newer PBM channels, and kept growing within customers already on our roster. This is the covered lives base we plan to activate through the 2027 benefit cycle, and we believe the momentum in place sets us up for a solid second half. Now let's shift to enrollment. Enrollment is where covered lives turn into Omada members. Let me highlight three items for the quarter. The first and most important is how broad our enrollment growth has been. As in Q1, Q2 growth was wide-ranging across our cardiometabolic suite, confirming that our momentum extends well beyond any single program. Since our last earnings call, we reached two key milestones that show how much breadth remains ahead. First, we launched cholesterol as a standalone care track for the very first time alongside one of America's largest retailers, and that initial engagement stands as an encouraging proof point of demand. Second, we've advanced prescribing discussions with channel partners and employers, including our first closed prescribing customer, slated to launch in 2027, which offers an early sign of market fit for this program. Taking that same idea further, revenue growth from our Diabetes and Hypertension Programs continued to substantially outpace our prevention and weight health program during Q2 — a favorable mix shift toward our higher value programs, one that underscores a 600% emphasis on that direction. On the question of how we keep expanding the platform — things like our GLP-1 suite and cholesterol — our belief is that enrollment will continue climbing over time. The second factor is the effectiveness of our enrollment engine. Email campaigns are the primary channel through which employees learn about our programs and sign up, and this year those campaigns converted at a rate about 20% higher than last year. We see that as a forward-looking signal of the health of our enrollment efforts, reflecting better targeting, personalization, and messaging directed at the exact same population. Seasonality is the third factor. Q1 was extraordinarily strong, and that strength pulled enrollments forward into earlier parts of the year. That benefits us for the rest of the year, because members who joined in Q1 are already in active care and generating revenue sooner. Typically, the overall member base grows throughout the entire year, but Q1 remains our largest window for new enrollment since that is when employers launch new benefits programs. The next major inflection point comes with the 2027 benefit cycle, when we expect millions of Americans to have the opportunity to enroll with Omada and receive treatment. Now I will move to engagement. Engagement is where members receive care from Omada, and it is where the durability of our business becomes visible. One notable signal from Q2 deserves attention. Members have stayed in active treatment with Omada nearly 10% longer than they did a year ago, driven by growth in our GLP-1, Diabetes, and Hypertension programs, where members have generally remained engaged on our platform for longer. This extends the ongoing investments in our platform, such as Omada Spark and Meal Map, along with the growing personalization and clinical depth we deliver in member care. Longer tenure in our programs generally means more billable months per member, greater lifetime value, and stronger margin per member as time passes. Let's turn now to how we deliver care and back this mission as a company. Our cost to serve has fallen over 10% year-over-year, measured as cost of revenue per member on a trailing 12-month basis. This has been driven by greater efficiency in delivering both digital and human care. On the human care side, we keep seeing capacity per care team member rise as we scale. We are applying AI and machine learning across all our support for the care team, from smarter tooling for our coaches, to improved prediction of member demand, to more standardized ways of working throughout our member-facing teams. Beyond the decline in the cost to deliver care, the wider business has grown more efficient too, in service of our mission. Even with significant investments to stand up new programs and channel partners, we have delivered 41% incremental adjusted EBITDA margin and brought non-GAAP operating expenses down from 68% of revenue a year ago to 62% this quarter, a 600% improvement in that expense ratio over the period. From where we sit, this demonstrates our ability to put money into Omada’s expansion while returns keep climbing—600%—and that’s the operating engine driving the margin improvement Steve is set to describe. Now that I’ve covered the operational picture, I’ll pass it over to Steve, who will take us through the figures.
Thanks, Wei-Li. Hi, everybody. Omada's second quarter was the best Q2 we've ever had. We hit quarterly records across the board: revenue came in at $88 million, gross margin reached 73% on a GAAP basis and 74% on a non-GAAP basis, net income was $5 million, and adjusted EBITDA was $11 million. Q2 also gave us our second quarter of GAAP net income profitability, after the fourth quarter of 2025. Those milestones matter a great deal for this business, and in our view they show the structural profitability of the model we're building. I'll go through Q2 keeping in mind the four operational drivers Wei-Li just walked through, and then I'll move to guidance and the balance sheet. Beginning with revenue: Q2 revenue totaled $88 million, which is up 43% year-over-year and up 13% sequentially versus Q1, powered by ongoing momentum in our GLP-1 Care Track, greater multi-condition penetration throughout our cardiometabolic suite, and steady gains in enrollment effectiveness. Within our Diabetes and Hypertension Programs, revenue growth kept exceeding our total revenue growth of 43%, which lines up with the enrollment breadth Wei-Li described. That revenue-driving activity is what's growing our member base, which brings me to something new we're sharing this quarter. We closed Q2 with roughly 1.1 million total members, an increase of 45% year-over-year, which mirrors the enrollment effectiveness Wei-Li described. As a reminder, for this purpose a member is defined as someone enrolled in one of our virtual care programs who generated a billing event during the preceding 12 months. Since we mostly bill based on the care activity members receive rather than a flat subscription, we think trailing 12-month revenue measured against that same 12-month member base is the most representative way to gauge our unit economics; by that measure, trailing 12-month revenue per total member came to $284 in Q2, versus $279 in Q2 of last year. In our view this assesses the unit economics of our member base, and we'd normally expect the metric to drift modestly upward or downward in any quarter as cohort mix, pricing mix, and seasonality move at the margin. What we've seen here has been consistent, which continues to reflect how durable our per member economics are. Now to gross margin: GAAP gross margin in Q2 was 73%, compared with 66% in Q2 of last year, which works out to roughly 700 basis points of year-over-year expansion. Non-GAAP gross margin was 74%, compared with 68% in Q2 of last year. The gross margin expansion this quarter came from a lower cost to serve our members, thanks to reduced care team delivery cost and supported by deeper multi-condition engagement as well as the maturation of our longer tenured cohorts. We've said before that we see a path to surpass our current long-term target of 70% annual gross margin. Our Q2 result fits that trajectory, and we'll update our long-term financial framework, gross margin included, at Investor Day. Now turning to operating costs, we achieved considerable operating leverage during this quarter. Under GAAP, operating expenses as a share of revenue dropped by roughly 6 percentage points, going from 73% to 69%. Under non-GAAP, the decline was also roughly 6 percentage points, moving from 68% to 62%. That leverage comes from the factors we've repeatedly highlighted: growing through channel partnerships, extracting more productivity from the sales team we already have, and maintaining strict cost control throughout the remainder of the business. AI also kept growing as an ever more significant contributor to our operating leverage. As we mentioned last quarter, we're assessing AI tools across all functions of the company, rather than focusing on just one area. As AI adoption grows deeper, we think it can keep supporting operating leverage as we head into 2027 and past that. GAAP net income in Q2 exceeded $5 million, versus a GAAP net loss of about $5 million during Q2 a year ago, which works out to an improvement of roughly $11 million year-over-year. This marks our second quarter of GAAP net income profitability, coming after the fourth quarter of 2025. Adjusted EBITDA in Q2 came in at roughly $11 million, an improvement of approximately $11 million year-over-year and a quarterly record for Omada; we think this adjusted EBITDA level in the second quarter showed our model's structural profitability delivering at scale, and it contributes meaningfully to the better full-year adjusted EBITDA outlook I'll get to shortly. Our strong profitability profile has kept bolstering a robust balance sheet too; we finished Q2 with cash and cash equivalents of about $222 million and still have no debt. Let me now shift to our outlook. Our remarkable second quarter results and ongoing visibility into the second half give us confidence to lift our full year 2026 outlook for both revenue and adjusted EBITDA. We're increasing full year revenue guidance to $334 million-$340 million, up from the earlier guidance of $322 million-$330 million. At the midpoint, that's roughly 30 percentage point revenue growth versus 2025; we're increasing full year adjusted EBITDA guidance to $21 million-$27 million, up from earlier guidance of $14 million-$20 million. At the midpoint, that's an improvement of about $18 million versus 2025, or approximately four times our 2025 result. Our increased outlook captures both Q2's remarkable strength and a more moderate second half growth trajectory, based on historic seasonality and contracted visibility. As Wei-Li said earlier, our business has traditionally followed a typical seasonal pattern in which Q1 is usually our strongest new enrollment period, with continued revenue contribution from that member base carrying through the rest of the year. In line with that pattern, our year-over-year growth rate should moderate during the second half as we lap an exceptionally strong first half enrollment period. We expect those first half enrollments to keep producing revenue at healthy per member economics, sustaining a strong margin profile through the remainder of 2026. The first quarter is still the biggest sign-up window we see annually, since that's when companies roll out fresh benefit offerings, and the following major step-up in enrollment activity arrives with the 2027 benefits cycle. During our Investor Day on September 10th, we'll present a refreshed long-range financial plan, covering the paths for growth, gross margin, and operating leverage that will guide how we run this business across the coming years. And with that, we'll begin taking your questions.
Yeah, thanks. Congratulations to Wei-Li and Sean on this transition. I'd like to begin with the AI efficiencies. Really impressive gross margin results compared to last year. Steve, like you said, that sort of gives you confidence regarding the longer-term outlook. Is there anything else you can tell us about how this is sort of flowing through, whether it's influencing your headcount choices as the business keeps scaling?
Hey, Craig. Sean speaking. Appreciate the congratulations. I'm really happy for Wei-Li. Regarding AI, like we've said on earlier calls, it remains a source of leverage and a key driver. That applies both to how we back our care teams and to the member experience too, spanning smarter tools for our coaches, improved forecasting of member demand, more consistent methods of working among our member-facing teams, plus the entire range of solutions we've introduced for members, such as Meal Map and Omada Spark. To underscore a few of the results we provided, noting that cost of revenue per member has fallen by more than 10%. As Wei-Li noted, members have remained active in Omada almost 10% longer than they did a year ago. This is something we'll keep pushing on, and we think it's beginning to appear in the numbers.
Great. Then, for my follow-up, Wei-Li, you mentioned that the second PBM partner is doing better than we expected. Could you tell us anything about what you picked up from the first partner and how things changed with it, and is that what's driving this, or is something else behind the strong pickup with the second one?
Yeah. Hi, Craig. I appreciate that question. Yeah, for years now we've had successful relationships with several of the leading PBMs in the country, so I'd like to believe we've built, within this industry, a rather solid playbook for how that ought to work. What we take away stays the same, whether it involves one of them, two of them, or three of them, and it breaks down as follows. One piece, naturally, is collaborating quite closely with their sales organizations. As all of you are aware, our own sales team is powerful in what it can do but limited in size, since we work hand in hand with the sales organizations at the PBMs and also at the health plans. That really helps amplify Omada's share of voice across a disproportionately large set of potential prospects that are now appearing in our pipeline. The next item I'd flag as significant is the product market fit of what we offer; we land right in the middle of virtually every conversation about health benefits, given where we stand with GLP-1s and, naturally, the wider discussion of cardiometabolic disease, which remains a leading cost driver for nearly every employer in America. That product market fit is a huge help, and it also generates plenty of interest and enthusiasm among the AEs, or sales staff, at the PBMs we work with. The final piece I'd mention that's taking shape is that our portfolio is quite broad across the cardiometabolic spectrum. Thanks to that partnership, our pipeline is building at a fairly healthy pace, with diversity across the cardiometabolic programs we offer. We're feeling good as we head into the closing season, which is opening up right at this moment.
Thanks a lot.
Hello, and thank you for fielding my questions. Congratulations on such a strong quarter, and congratulations to you too, Wei-Li. Sean, naturally, I wish you the best — you've certainly earned the chance to ease back a bit. Wei-Li, I'd like to build on that final point you made regarding how varied your pipeline is, since I believe the investment community sometimes lumps Omada into a single category — essentially, that it's merely a GLP-1 beneficiary and that this whole decision-making period is just a short-term phenomenon. Could you discuss how, while this clearly spans many programs and isn't limited to GLP-1s, there's a wider conversation happening—what do you believe is striking a chord among your customers and partners, bringing a broader cardiometabolic health dialogue to the forefront at this moment?
Yeah. That's a great question. We've said for quite a while that upon entering the GLP-1 area a number of years ago, it serves in some ways as a route into a larger cardiometabolic condition. If you ask employers — and the Mercer and Aon surveys back this up every year — what they care about most, the answer lines up with whichever condition drives their biggest costs. Year in and year out, heart disease, metabolic conditions, obesity, diabetes, heart attacks, and strokes rank in the top five, often taking up several of those slots. It never leaves their minds. And then, of course, there's the pressure and demand surrounding GLP-1s, which only pushes the cardiometabolic conversation further to the forefront. It's a real advantage for us to be in a position to play in both of those areas, because our cardiometabolic offerings are comprehensive — they reach from Diabetes Prevention and Hypertension all the way to Diabetes Management. And, naturally, we just recently made an announcement about our cholesterol program, and that one is doing very well out in the market. On top of that, we have a full suite and complement of GLP-1 care programs, including the launch and announcement we made most recently of our prescribing program, which pairs with our wraparound support service. A good number of those solutions have been tailored by us to meet the many distinct needs that GLP-1 customers have out there in the marketplace. If you pull back and look at the market, and employers do the same, asking themselves, "What's the best way to tackle these main problem areas?" — what they typically discover is that Omada sits right at the center, offering the most comprehensive and extensive cardiometabolic solution available. Add to that our reach through channels and our spread across the leading three PBMs plus many, many health plans, and getting Omada up and running becomes simple. It comes down to how wide and deep our program goes, the results we deliver, and the fairly straightforward process of signing a contract and integrating us into the company. Our customer base is responding to that really strongly. Our pipeline shows variety in that respect. It's likely also worth pointing out that we're seeing broader diversification across channels as well; over the past several years, we've been working fairly diligently on this front. We've added CVS, Optum Rx, the complete set of our cardiometabolic offerings, plus our GLP-1 offerings. Just recently, as we shared in our earnings press release, there's the expansion with HCSC. Diversifying channels has mattered too, and it serves as an early signal for diversifying revenue. All of this is coming to fruition in our pipeline, which we'll be converting during H2. We feel good about how that positions us for 2027.
Ryan, let me just tack on one final point here. As we mentioned in parts of the prepared remarks, our Diabetes and Hypertension books stood out as the two fastest-growing books year over year during the second quarter, each above 50%. That matters a great deal to us, since these rank among our highest-priced products. These members remain in the program the longest and have the longest duration. GLPs have genuinely served as that opening conversation, after which we can circle back and sell across the whole product suite, and that has proven quite beneficial for us economically.
Thanks for flagging that, Steve, it’s an important point. Maybe one more for you as a follow-up. Clearly the business is performing exceptionally well; the numbers make that obvious. Could you unpack a bit what is assumed in the guidance for the second half of the year? As we worked through what it would take to reach the upper end of the top-line guide, it looks like if revenue simply stays flat from Q2 into Q3 and Q4, you end up near the high side of the range. Is there anything specific you would point to there, or do member counts begin to fall in the back half? I’m just trying to get a sense of what is embedded in the top-line guidance. Thanks.
Yeah, absolutely, glad to add some context. Q2 was obviously a terrific quarter for us. As noted in some of the prepared remarks and in what Wei-Li shared, we anticipate 2026 will be a more normalized year. Our usual rhythm is to use the second half to develop new pipeline and sign new employer clients, then we go live in the first half of the following year. That is exactly what played out in the first half of 2026. We had an extremely strong selling season during the back half of 2025, and then saw member growth above 40% in both Q1 and Q2 of this year, along with revenue growth above 40% in each of those quarters as well. One thing worth keeping in mind is that we are comparing against a very robust 2025, when revenue growth in the back half was 54%; during that stretch we were scaling into one of our largest channel partners across multiple lines of business. For 2026, the cadence is more typical for us from a seasonality standpoint.
Hello, Kalia is here standing in for Saket. We appreciate you fielding our question, and congratulations go out to Sean as well as Wei-Li. A key element of this narrative, as I see it, is the way chronic condition prevalence across the U.S. generates a substantial TAM that Omada can pursue, especially with its strategy of addressing multiple conditions. When we peer ahead to 2026 and later, Omada now possesses a larger platform to market, featuring GLP-1 prescription, Flexcare, plus the newly introduced cholesterol program. Could you explain how these added offerings are widening the TAM available to Omada, and how that might factor into the growth equation over the longer horizon?
Yes. Sean speaking. Something that gets us very enthusiastic is just how nascent these markets remain, and that applies not only to Omada but to the entire upcoming generation of digital health businesses. Looking at where we stood at the close of last year, we had approximately 8% of the ASO market, 10% of the fully insured market, and about 1% MA. There's an abundance of untapped opportunity. The expansions we've made public, as we've mentioned previously, come directly from customer demand. What's taking place is that each year the incumbent traditional healthcare system simply lets down patients and lets down the clients footing the bill, so those clients are demanding something different. That something different is what we've built, in the form of care delivered between visits that taps into technology, cost-effective care services, and distinctive experiences. This is what brought about the expansions. As I noted during our first earnings call of this year, we've brought more new program capabilities to market during this year than at any other point in Omada's history, and we're fortunate to have the strongest channel landscape and selling landscape that Omada has ever had. Naturally, our entire focus is on building the groundwork to take advantage of that, both in the latter half of this year and throughout next year.
Fantastic. I really appreciate it.
Absolutely, thanks for taking these questions. Sean, well done. Wei-Li, well done too. Sean, I'm hoping you'll still be around going forward.
Thanks, Richard.
Thanks for the thoughts on enrollment and seasonality. Thinking about it a bit further, during the prior year you saw fairly significant quarter-over-quarter increases. Clearly, it sounds like this year those increases won't be as pronounced. And since diabetes and hypertension programs are expanding at the quickest rate, I'm wondering whether this signals anything regarding GLP-1s — that perhaps employers are saying, "Hey, we won't cover these for weight loss," and letting workers go straight to consumer? Could it be that your GLP-1 suite has eased off somewhat relative to the prior year when it comes to growth?
Yes. Hello, Richard. It's Wei-Li. Allow me to tackle that from a market perspective and based on what we're hearing. Look, right now we're in the midst of that point in the year when employers assess what they will cover and what they won't. It's likely intuitive and reasonable to assume that a certain number of employers are looking at broadening coverage of GLP-1s for weight loss while others are stepping away. We read the headlines and such on both sides of those coverage choices. Throughout our book of business, we're observing both of those scenarios happening; predicting is difficult and probably not the appropriate thing to do, since everyone is simply making their decisions at this moment, so we'll need to see where that lands by year-end. What I will say is the thing most important for people to keep in mind is that, whether you're an employer currently covering GLP-1s or one that will come in the 2027 year, we offer a range of prescribing plus wraparound GLP-1 support lifestyle services capable of boosting the outcomes and ROI of that specific investment. We feel extremely well positioned when it comes to product market fit there, particularly given the channel penetration and diversification we possess at the PBM as well as the health plan level covering those benefits; conversely, for those employers keeping a non-GLP-1 coverage situation as they go into next year for weight loss or ending their coverage, it's simple to mistakenly believe that perhaps we lack opportunity there, and nothing could be further from the truth. That really comes in two ways. The first is that with the introduction of our GLP-1 Flex Care program, along with our partnership with the Lilly Employer Connect program, we can appeal to employers who frequently care about delivering good clinical support, that clinical layer, irrespective of whether they cover for GLP-1s, knowing their employees are going direct to consumer or other direct channels and paying cash. There's a fair amount of curiosity around that space, since an employer can provide clinical assistance—a layer like Omada—and still see returns when staff decide to spend their own money through direct purchasing routes for GLP-1s. That's the spot we're in, Omada is, with product-market fit on either side, so from an opportunity perspective we consider ourselves protected, and that seems correct too. Another point worth mentioning: for those employers who've chosen not to include GLP-1s, they continue to see elevated healthcare resource utilization broadly within cardiometabolic. We gently point out that we offer an entire range of cardiometabolic offerings—Richard, you know these well—which they often weigh in such situations, since their workers still require help no matter what they've decided about covering GLP-1s.
All right, thank you. And perhaps to build on that, I'd like to know about fresh program possibilities — clearly you got the prescribing launch out the door quite fast, followed by cholesterol, and now you're bringing AI into the mix. So when it comes to the roadmap for new products or programs, does that lean more toward developing things in-house, or toward M&A, the way we saw another company do earlier this week?
Yes. Richard, as we've mentioned previously, and this aligns with what we'll tell you today, our platform is something we're very fond of; we believe it's connecting well with the marketplace. Each year, when we hold our consultations with accounts, we put the question to them: "What's the next step for us?" Each year, they bring us suggestions. Whether we act on those suggestions or hold steady is essentially up to us. Most importantly, the manner in which we've constructed the technology, the infrastructure, and the operations at Omada — as demonstrated by our achievements, and by what we've accomplished beyond prevention, which Steve pointed to in areas like diabetes and hypertension, and so on — means we possess what's needed to support multiple products. I believe that over the long span of this journey, we'll keep listening with an open mind to our customers and proceed from there. As things stand, we're serving vast populations at a pivotal point of need in the market.
Thank you, and congratulations.
Thanks. Richard, I might just add something onto what you said there. You touched a bit on where our roadmap is headed. What I'd tell you is that you can count on us putting more resources into AI and bringing that to scale within our application experience, and making certain that it's powering an experience that's empathetic and human-centered. That's something we'll keep pushing forward, and we'll build out further what we're doing with Omada Spark, along with AI inside the application. Then, the second point, when it comes to the GLP-1 landscape — look, nothing has really settled down. It remains dynamic out there. I think that's clear to all of us. You can be sure that our customers, and others listening on this call too, can count on us continuing to put money into innovating our GLP-1 offerings, whenever the needs come up.
Okay, thanks a lot.
Hello, I'm Chris Charlton, filling in for Sean today. We appreciate you answering our questions, and congratulations to Wei-Li and Sean. Could you give us some insight into what's driving the revised EBITDA guidance? You posted roughly a 12% margin this quarter, yet the guidance midpoints suggest about a 7% margin across the second half. That's a bit of a step down. I appreciate the details you provided regarding revenue seasonality and how it relates to member enrollment peaking early in the year. I’d like to ask whether there’s any EBITDA seasonality we ought to factor in — for example, spending ahead of time to support member sign-ups early in the year — or whether this connects more to other factors, like gross margin easing or extra spending on AI or marketing. Thank you.
No, that’s exactly right. Essentially, two major things are going on. During our Q1 call, we explained that we wanted to pull a great deal of investment forward to the start of this year, particularly into Q1. Over that first quarter, we brought on about 50 people, spanning go-to-market and R&D. Those individuals typically began under a mid-quarter convention in Q1. At this point, those costs are being annualized across the full run rate for Q2 and the remainder of the year. Through the back half, we'll add a modest amount of headcount, though you should anticipate that OpEx stays more or less level—or possibly rises a touch in H2. Given the seasonality remarks tied to revenue, an implied slight decline does exist, and that's what produces the modest retreat in overall EBITDA margin. On the whole, none of this comes as a surprise. It fits within how our business ordinarily moves, and we're focused on positioning ourselves to begin 2027 strongly while generating ROI from those investments.
Excellent, that's really useful. Regarding the cholesterol program, now that it's been rolled out, can you tell us anything additional about its pricing and how it stacks up against other options, plus any further insight into how demand is trending? Thanks.
Sure. Hello, I'm Wei-Li. When it comes to what we charge for cholesterol, it adds to both our top line and our gross margin. We've said for a long while, "Look, if you'd like to set aside a band for our programs running from $50, $60 at the lower end up to $90 at the upper end, cholesterol fits comfortably inside that band. Likely closer to our prevention product." That's roughly where it stands. I believe the key thing to think about with cholesterol regarding the opportunity is that there's the price and the ARPU side, and there's the demand and volume side. If you pull back and examine the cardiometabolic profile of many individuals, frequently, cholesterol is among those conditions that's fairly silent, and is undertreated at the primary care level. There's an enormous opportunity there as we partner with people who have diabetes and hypertension. Then to clearly upsell or cross-sell into the cholesterol program and simply adopt a more holistic care approach, thus enhancing their outcomes. Their cholesterol program is as much about selling more in the sense of additional products into our client bases as it is about synergizing with the rest of the cardiometabolic products we have, thereby confirming greater total ROI for that particular patient profile for a company.
All right, excellent. Thanks once more, and congratulations on the quarter.
Hello. Nice work on the strong quarter. Could you expand a bit on the ties you have with the major PBMs? Of your members, what share would you now classify as GLP-1 members? My understanding is it's around under 20% of the total, which strikes me as favorable since there's lots of room left to sell. Regarding those PBM relationships, could you address the reporting that goes back to the self-insured employer client? Is it possible for them to view who is enrolled in the program, the amount of weight every member has shed, how total claims trend is affected, and similar items? Many thanks.
Yes, absolutely; Wei-Li here. I'll speak to the ties with the major PBMs and the specifics of reporting, and similar matters. After that I'll hand things to Steve to discuss the percentage of revenue from GLP-1s and similar items, and the contribution there. Broadly speaking, the way we work with our PBMs mirrors the way we work with health plans, in that we sign contracts with them for provider services. In this instance, among the three PBMs, every one of our cardiometabolic programs, such as diabetes, Diabetes Prevention, Hypertension, MSK, cholesterol, given that we introduced it earlier this year, frequently isn't included in those contracts, though we are certainly looking to upsell that in. That's the contractual side of things. As for the actual sales motion, in case you were curious, it works much like what we do with health plans. We work alongside the account executives at the PBM level to build awareness among their client books of business. We go to market jointly with them, we generate outreach to them. We finalize deals alongside them, just as we would in other relationships we hold; we handle the deployment. By deployment I mean we roll out the program with the employers to their employee base, and in most instances carry out all the enrollment outreach; that's typically how we generate membership through those channels. When it comes to reporting, your question gets a yes. It makes no difference if you hold a direct contract with us or you're contracting us via a health plan or any of the big three PBMs. What we'll provide is a set of reports that describe, for example, how deployment is progressing, what the penetration and enrollment rate are, what members are doing within the application, and how they're interacting with their care teams? As the business expands, clearly the count of employees we serve rises. We naturally start reporting out not only on utilization engagement, but on outcomes too. Was their blood glucose under control? Was their weight under control? Was their blood pressure under control? And continuing in that way, so that the people buying from us can be persuaded we're delivering the worth to their workers and to their operations that we described while selling; that's roughly the way we collaborate with the PBMs and the way we report.
Sure, I want to give a bit more detail regarding what we said about the GLP-1 mix. In last year's Q4 report, 150,000 members were enrolled in our GLP-1 program, out of 887,000 overall. As we've moved into Q2, that proportion has stayed about the same. We're still seeing wide-ranging momentum across every one of our product sets, and GLP-1s remain a major force behind that expansion.
Hey, everyone. Ayush here, filling in for Elizabeth. Appreciate you taking my question. Regarding the HCSC expansion, where roughly 1.5 million covered lives get added across the fully insured book, do those fully insured lives become enrolled members at the same rate as self-insured ones, and when do we expect those lives to begin enrolling? On the retailer cholesterol deployment, is that account brand new to Omada altogether, or is it a current multi-condition client that's adding cholesterol?
Hi, Ayush; Wei-Li here. I'll handle both of those for you; regarding the HCSC expansion, our relationship with them goes back a long way, covering both their ASO book and a couple of states for their fully insured book. That 1.5 million or so expansion refers to an additional three-state expansion inside the HCSC book. The implication behind your question, I'd say, is right, in that when it comes to the fully insured book of business, the Omada programs, here Prevention and Hypertension, are completely embedded in the benefit. No downstream sales cycle is needed for employers; deployment comes back faster. What should we expect? We're working hard with HCSC to get that set up and deployed. Revenue ought to begin hitting the books across H1 of next year and clearly continuing after that point. When it comes to cholesterol, we announced earlier in the year that we quickly closed that large retailer. We have plenty of other cholesterol deals in our pipeline. Given the short sales cycle, you can probably guess it was a current customer. That's indeed what happened. We're already seeing significant enrollments from that. What matters there, I think, is that this quick upsell for a very large client strikes us as a strong lead indicator for product market fit and traction. If you looked into our CRM, you'd find within our pipeline a number of cholesterol deals, not just upsells for current clients, but also new logos. We feel good about the momentum heading into the back half of this year for our closing season and are excited about it for 2027.
Thanks a lot. Right now, I see that there aren't any more questions. That brings our program to an end. You can go ahead and disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Omada Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Omada Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.